ABVC BioPharma, Inc.
ABVC BioPharma, Inc.
Your view on ABVC
Overview
What the company does, where it operates, and who runs it.
About ABVC BioPharma, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Uttam Yashwant Patil
- Headquarters
- 44370 Old Warm Springs Boulevard, Fremont, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Uttam Yashwant Patil
- Headquarters
- 44370 Old Warm Springs Boulevard, Fremont, CA, US
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.
The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage.
It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for ABVC BioPharma, Inc. from FRC's valuation model, read against the market price. ABVC last traded at $0.94; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for ABVC BioPharma, Inc.. Starting points for ABVC BioPharma, Inc.: EPS -$0.18, beta 0.50 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for ABVC BioPharma, Inc.. ABVC BioPharma, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for ABVC BioPharma, Inc.. Trailing twelve-month EPS for ABVC BioPharma, Inc. stands at -$0.18. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Analyst Ratings
- Strong Buy0
- Buy0
- Hold1
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 |
|---|---|---|---|
| Avg. estimate | -$0.40 | -$0.40 | $1.30 |
| Low estimate | -$0.40 | -$0.40 | $1.30 |
| High estimate | -$0.40 | -$0.40 | $1.30 |
| No. of analysts | 1 | 1 | 1 |
| Year-ago EPS | -$0.121 | -$0.061 | -$0.391 |
| Growth | — | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 |
|---|---|---|---|
| Avg. estimate | $113257.00 | $144441.00 | $35.28M |
| Low estimate | $113257.00 | $144441.00 | $35.28M |
| High estimate | $113257.00 | $144441.00 | $35.28M |
| No. of analysts | 1 | 1 | 1 |
| Year-ago revenue | -$795950.00 | $0.00 | $0.00 |
| Growth | +114.2% | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for ABVC BioPharma, Inc.. ABVC BioPharma, Inc. has reported as a listed company since 2004. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ATNMActinium Pharmaceuticals, Inc.Biotechnology$47M
- GRCEGrace Therapeutics, Inc.Biotechnology$28M
- JUNSJupiter Neurosciences, Inc.Biotechnology$2M
- LTRNLantern Pharma Inc.Biotechnology$6M
- PDSBPDS Biotechnology CorporationBiotechnology$52M
- RVPHReviva Pharmaceuticals Holdings, Inc.Biotechnology$36M
More Biotechnology companies
- RNAAvidity Biosciences, Inc.NASDAQ$139M
- RNACCartesian Therapeutics, Inc.NASDAQ$185M
- RNAZTransCode Therapeutics, Inc.NASDAQ$1M
- RNTXRein Therapeutics Inc.NASDAQ$35M
- RNUGFReNeuron Group plcOTC$62,891
- RNXTRenovoRx, Inc.NASDAQ$46M
- ROIVRoivant Sciences Ltd.NASDAQ$28.0B
- RVLPQRVL Pharmaceuticals plcOTC$1,114
- RVMDRevolution Medicines, Inc.NASDAQ$36.1B
- RVMDWRevolution Medicines, Inc. WarrantNASDAQ$34.1B
- RVX.TOResverlogix Corp.TSX$26M
ETFs holding ABVC BioPharma, Inc.
% of the fund
- VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
- VXFVanguard Extended Market ETF$30.2B in assets0.00%
- VUN.TOVanguard U.S. Total Market Index ETF$20.1B in assets0.00%
- VEQT.TOVanguard All-Equity ETF Portfolio$17.6B in assets0.00%
- VGRO.TOVanguard Growth ETF Portfolio$10.9B in assets0.00%
- VBAL.TOVanguard Balanced ETF Portfolio$6.0B in assets
- VUS.TOVanguard U.S. Total Market Index ETF (CAD-hedged)$1.4B in assets0.00%
- VCNS.TOVanguard Conservative ETF Portfolio$977M in assets
Largest holders first, then the funds most concentrated in ABVC.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by ABVC BioPharma, Inc. executives and directors. Shares of ABVC BioPharma, Inc. have traded between $0.40 and $5.48 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for ABVC BioPharma, Inc.. Coverage tracks ABVC BioPharma, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of ABVC BioPharma, Inc.